National Medical Insurance Administration: The expert review of the adjustment of the medical insurance drug catalog has ended

icon-192x192.png

Visit the original URL
The National Medical Insurance Bureau issued an announcement on October 16. According to the “2022 National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog Adjustment Work Plan”, the National Medical Insurance Bureau organized experts to pass the national basic medical insurance, work injury insurance and maternity insurance in 2022. The drug list (hereinafter referred to as the 2022 National Medical Insurance Drug List) has undergone a comprehensive review of the declared drugs for the adjustment form review. At present, the expert review work has ended.

Each applicant enterprise can log in to the “2022 National Medical Insurance Drug Catalog Adjustment Application” module of the National Medical Insurance Service Platform (fuwu.nhsa.gov.cn) to inquire about the expert review results. The results of the review are “new to be negotiated”, “to be added to bidding”, “to be negotiated to renew”, “to be simple to renew”, etc. Among them, if the review result is “new to be negotiated” or “to be added to bidding”, it means that the drug has been included in the scope of negotiation/bidding of the National Medical Insurance Drug List in 2022 and obtained the qualification for negotiation/bidding, which does not mean that the drug has been included in the 2022 Annual National Medical Insurance Drug List. (CCTV News)
media coverage

36Kr
Related events

This article is reprinted from: https://readhub.cn/topic/8k8QBCKkidh
This site is for inclusion only, and the copyright belongs to the original author.